BAJAJHCARENSEBajaj Healthcare Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 16 Jan, 2026 · 18:24 IST

Bajaj Healthcare Q3 results: revenue up 31% YoY; board re-appoints 4 directors

BAJAJHCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-0.3%Reaction day
₹389.30
prior close
₹395.00
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-1.3%+1.0% vs market
Pharmaceuticals peers, median of 158sector-0.8%+0.5% vs sector

On the reaction day the stock moved 1.0 pts more than Nifty Microcap 250 and 0.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+5.3
10m
+1.3
15m
+2.0
30m
+2.1
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-0.3-1.3+1.0-0.8+0.5
Next day
-5.0-4.0-1.0-3.1-1.9
2d
-7.0-4.8-2.2-4.1-2.9
3d
-7.8-3.3-4.5-2.9-4.9
4d
-10.6-5.3-5.3-4.3-6.3
5d
-14.0-5.2-8.8-4.6-9.4
1w
-6.8-3.7-3.1-4.0-2.7
15d
-2.4+3.6-6.0-1.1-1.3
1m
-8.2+0.1-8.3-2.4-5.7
2m
-22.2-8.9-13.3-9.4-12.7
3m
-14.7+3.2-17.9-1.0-13.7
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 158Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bajaj Healthcare reported Q3 FY26 revenue of Rs 16,122 lakhs, up 31% YoY from Rs 12,279 lakhs. Profit before tax jumped 65% YoY to Rs 1,924 lakhs. For 9M FY26, revenue rose 18% to Rs 45,797 lakhs and profit after tax grew 30% to Rs 4,072 lakhs. The board also re-appointed four directors for 3-year terms: Sajankumar Bajaj as Chairman and MD, Anil Jain as MD, Namrata Bajaj and Pakshal Jain as Whole-Time Directors. A postal ballot will seek shareholder approval.

Likely market impact

Strong quarterly results show growth momentum. Director re-appointments ensure management continuity but need shareholder nod.